Zoetis (ZTS) Debt/Equity Ratio: History & Chart

Zoetis Inc.(ZTS)

Drug Manufacturers - Specialty & Generic · Parsippany, NJ

$74.72-1.09 (-1.44%)

Delayed quote: Sep 8, 2026, 11:05 AM EDT

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ

14,500 employees

www.zoetis.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Kristin C. Peck

View full financials

ZTS Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

2.93

DEBT TO EQUITY RATIO AVG TTM

2.27

DEBT TO EQUITY RATIO AVG 3Y

1.37

DEBT TO EQUITY RATIO AVG 5Y

1.42

DEBT TO EQUITY RATIO AVG 10Y

2.13

DEBT TO EQUITY RATIO AVG 15Y

2.17

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+29.23%

CURRENT VS 3Y AVG

+114.18%

CURRENT VS 5Y AVG

+106.31%

CURRENT VS 10Y AVG

+37.67%

CURRENT VS 15Y AVG

+35.48%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.69

median of 83 covered companies

CURRENT VS SECTOR MEDIAN

+325.30%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Zoetis Inc. (ZTS)	$31.32B	2.93	2.27	1.37	1.42
Biogen Inc. (BIIB)vs ›	$31.62B	0.44	0.39	0.44	0.53
DexCom, Inc. (DXCM)vs ›	$32.12B	0.53	0.87	1.00	1.01
GE HealthCare Technologies Inc. (GEHC)vs ›	$30.47B	0.92	1.04	1.09	0.74
ResMed Inc. (RMD)vs ›	$32.14B	0.13	0.14	0.21	0.23
Centene Corp. (CNC)vs ›	$32.45B	0.71	0.84	0.83	0.81
Waters Corporation (WAT)vs ›	$30.16B	0.35	0.76	1.73	2.93
Medline Inc. (MDLN)vs ›	$29.59B	1.09	1.09	1.06	1.06
Alcon Inc. (ALC)vs ›	$33.70B	0.25	0.24	0.25	0.24
Alnylam Pharmaceuticals, Inc. (ALNY)vs ›	$35.34B	0.94	10.47	10.47	5.79

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Zoetis Inc. (ZTS)

$31.32B

2.93

2.27

1.37

1.42

Biogen Inc. (BIIB)vs ›

$31.62B

0.44

0.39

0.44

0.53

DexCom, Inc. (DXCM)vs ›

$32.12B

0.53

0.87

1.00

1.01

GE HealthCare Technologies Inc. (GEHC)vs ›

$30.47B

0.92

1.04

1.09

0.74

ResMed Inc. (RMD)vs ›

$32.14B

0.13

0.14

0.21

0.23

Centene Corp. (CNC)vs ›

$32.45B

0.71

0.84

0.83

0.81

Waters Corporation (WAT)vs ›

$30.16B

0.35

0.76

1.73

2.93

Medline Inc. (MDLN)vs ›

$29.59B

1.09

1.06

Alcon Inc. (ALC)vs ›

$33.70B

0.25

0.24

0.25

0.24

Alnylam Pharmaceuticals, Inc. (ALNY)vs ›

$35.34B

0.94

10.47

5.79

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Zoetis Inc. (ZTS)?

The debt to equity ratio for ZTS stock is 2.93.

Is Zoetis Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 2.93 is 106% above its 5-year average of 1.42, near the high end of its 5-year range (1.29–2.93).

What is the TTM average debt to equity ratio for Zoetis Inc. (ZTS)?

The TTM average debt to equity ratio for ZTS stock is 2.27.

What is the 3Y average debt to equity ratio for Zoetis Inc. (ZTS)?

The 3Y average debt to equity ratio for ZTS stock is 1.37.

What is the 5Y average debt to equity ratio for Zoetis Inc. (ZTS)?

The 5Y average debt to equity ratio for ZTS stock is 1.42.

What is the 10Y average debt to equity ratio for Zoetis Inc. (ZTS)?

The 10Y average debt to equity ratio for ZTS stock is 2.13.

What is the 15Y average debt to equity ratio for Zoetis Inc. (ZTS)?

The 15Y average debt to equity ratio for ZTS stock is 2.17.

DATE	DEBT TO EQUITY RATIO
2026-06-30	2.93
2026-03-31	2.86
2025-12-31	2.85
2025-09-30	1.35
2025-06-30	1.36
2025-03-31	1.45
2024-12-31	1.41
2024-09-30	1.29
2024-06-30	1.36
2024-03-31	1.34
2023-12-31	1.35
2023-09-30	1.33
2023-06-30	1.46
2023-03-31	1.50
2022-12-31	1.84
2022-09-30	1.45
2022-06-30	1.47
2022-03-31	1.45
2021-12-31	1.48
2021-09-30	1.44
2021-06-30	1.69
2021-03-31	1.80
2020-12-31	1.95
2020-09-30	2.18
2020-06-30	2.63
2020-03-31	2.41
2019-12-31	2.44
2019-09-30	2.48
2019-06-30	2.74
2019-03-31	2.84
2018-12-31	2.95
2018-09-30	3.04
2018-06-30	2.52
2018-03-31	2.53
2017-12-31	2.80
2017-10-01	2.87
2017-07-02	2.66
2017-04-02	2.78
2016-12-31	3.00
2016-10-02	2.82
2016-07-03	3.29
2016-04-03	3.84
2015-12-31	4.56
2015-09-27	2.96
2015-06-28	3.10
2015-03-29	2.85
2014-12-31	2.77
2014-09-28	2.68
2014-06-29	2.90
2014-03-30	3.40
2013-12-31	3.89
2013-09-29	4.33
2013-06-30	4.57
2013-03-31	5.14
2012-12-31	0.14
2012-09-30	0.14
2012-06-30	0.15
2012-03-31	0.15
2011-12-31	0.15
2011-09-30	0.00
2011-06-30	0.00
2011-03-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

2.93

2026-03-31

2.86

2025-12-31

2.85

2025-09-30

1.35

2025-06-30

1.36

2025-03-31

1.45

2024-12-31

1.41

2024-09-30

1.29

2024-06-30

1.36

2024-03-31

1.34

2023-12-31

1.35

2023-09-30

1.33

2023-06-30

1.46

2023-03-31

1.50

2022-12-31

1.84

2022-09-30

1.45

2022-06-30

1.47

2022-03-31

1.45

2021-12-31

1.48

2021-09-30

1.44

2021-06-30

1.69

2021-03-31

1.80

2020-12-31

1.95

2020-09-30

2.18

2020-06-30

2.63

2020-03-31

2.41

2019-12-31

2.44

2019-09-30

2.48

2019-06-30

2.74

2019-03-31

2.84

2018-12-31

2.95

2018-09-30

3.04

2018-06-30

2.52

2018-03-31

2.53

2017-12-31

2.80

2017-10-01

2.87

2017-07-02

2.66

2017-04-02

2.78

2016-12-31

3.00

2016-10-02

2.82

2016-07-03

3.29

2016-04-03

3.84

2015-12-31

4.56

2015-09-27

2.96

2015-06-28

3.10

2015-03-29

2.85

2014-12-31

2.77

2014-09-28

2.68

2014-06-29

2.90

2014-03-30

3.40

2013-12-31

3.89

2013-09-29

4.33

2013-06-30

4.57

2013-03-31

5.14

2012-12-31

0.14

2012-09-30

0.14

2012-06-30

0.15

2012-03-31

0.15

2011-12-31

0.15

2011-09-30

0.00

2011-06-30

0.00

2011-03-31

0.00

Debt to Equity Ratio: 2.93

ZTS Debt to Equity Ratio

ZTS Average Debt to Equity Ratio Chart

ZTS Current vs Average Debt to Equity Ratio Chart

ZTS Debt to Equity Ratio Metrics

ZTS Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

ZTS Debt to Equity Ratio History

Related Metrics